Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2010

 
 
 

Ceftobiprole  

  • Bäckström T, Panagiotidis G, Beck O, Asker-Hagelberg C, Rashid M-U, Weintraub A, Nord CE. Effect of ceftobiprole on the normal human intestinal microflora. Int J Antimicrob Agents. 2010; 36(6): 537-541.
  • Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother. 2010; 54(11): 4900-4902.
  • Betriu C, Culebras E, Gómez M, López-Fabal F, Rodríguez-Avial I, Picazo JJ. Comparative in vitro activity of ceftobiprole against Gram-positive cocci. Int J Antimicrob Agents. 2010; 36(2): 111-113.
  • Borbone S, Campanile F, Bongiorno D, Stefani S. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin resistant Staphylococcus aureus. J Antimicrob Chemother. 2010; 65(3): 591-594.
  • Bustos C, del Pozo JL. Emerging agents to combat complicated and resistant infections: Focus on ceftobiprole. Infect Drug Resist. 2010; 3(1): 5-14.
  • Candeloro C, Delamere K. Aortic graft vancomycin intermediate resistant staphylococcus aureus infection treated with ceftobiprole after linezolid induced peripheral neuropathy. Can J Hosp Pharm. 2010; 63(1): 70.
  • Chahine EB. Ceftobiprole: Farewell or just a delay? Am J Health-Syst Pharm. 2010; 67(12): 981.
  • Chaubey V, Dalton B, Sabuda D, Parkins M, Zhang K, Gregson D, Conly J. Ceftobiprole use in methicillin resistant staphylococcus aureus (MRSA) bacteremia and pneumonia. Can J Infect Dis Med Microbiol. 2010; 21: 38A.  
  • Cattoir V, Daurel C. Update on antimicrobial chemotherapy. Med Mal Infect. 2010; 40(3): 135-154.
  • Curcio D. New antibiotics: Which role in a antimicrobial stewardship program? Int J Infect Dis. 2010; 14: e315.
  • Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health-Syst Pharm. 2010; 67(12): 983-993. 
  • Davies TA, He W, Bush K, Flamm RK. Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin. Antimicrob Agents Chemother. 2010; 54(10): 4510-4512.
  • DeCorby M, Weshnoweski B, Vashisht R, Wierzbowski A, Simner P, Tailor F, Lagace-Wiens P, Walkty A, McCracken M, Mulvey MR, Karlowsky JA, Adam HJ, Hoban DJ, Zhanel GG. Antimicrobial resistance in pathogens isolated from Canadian hospital clinics, emergency rooms, medical/surgical wards and intensive care units: Results of the canward 2009 study. Can J Infect Dis Med Microbiol. 2010; 21: 9A. 
  • Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant staphylococcus aureus in diabetic foot infections. Drugs. 2010; 70(14): 1785-1797. 
  • Entenza JM, Vouillamoz J, Bizzini A, Giddey M, Bille J, Moreillon P. In vitro synergism between ceftobiprole and vancomycin against methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Clin Microbiol Infect. 2010; 16: S9.
  • Farrell D, Moet G, Sader H, Putnam S, Jones R. Ceftobiprole activity when tested against clinical bacterial pathogens from Europe, 2009. Clin Microbiol Infect. 2010; 16: S556.
  • Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(1): 116-125.
  • Golan Y, McDermott L, Snydman DR. Trends in ceftobiprole susceptibility among 2001-2008 consecutive methicillin-resistant Staphylococcus aureus blood isolates. Clin Microbiol Infect. 2010; 16: S251-S252.
  • Henry X, Amoroso A, Coyette J, Joris B. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob Agents Chemother. 2010; 54(2): 953-955.
  • Hsueh P-R, Lee S-Y, Perng C-L, Chang T-Y, Lu J-J. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital. Int J Antimicrob Agents. 2010.
  • Kongnakorn T, Baker TM, Akhras K, Merchant S, Mwamburi M, Caro JJ. Economic evaluation of ceftobiprole for the treatment of complicated skin and skin structure infections in the United States. Value Health. 2010; 13(3): A192-A193. 
  • Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti-Infect Ther. 2010; 8(11): 1293-1305.
  • MacDonald A, Dow G. Ceftobiprole: First reported experience in osteomyelitis. Can J Infect Dis Med Microbiol. 2010; 21(3): 138-140.    
  • Nannini EC, Stryjewski ME, Singh KV, Rude TH, Ralph Corey G, Fowler Jr VG, Murray BE. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(5): 2206-2208.
  • Panagiotidis G, Backstrom T, Asker-Hagelberg C, Rashid M, Weintraub A, Nord CE. Effect of ceftobiprole on the normal human intestinal microflora. Clin Microbiol Infect. 2010 16: S342.
  • Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother. 2010; 65(9): 1853-1861.
  • Queenan AM, Shang W, Bush K, Flamm RK. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob Agents Chemother. 2010; 54(10): 4092-4097.
  • Saravolatz LD, Pawlak J, Johnson LB, Saravolatz LD, Husain N. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents. 2010; 36(5): 478-480. 
  • Seifert H, Gatermann S, Pfister W, Poehlmann C, Huhulescu S, Muehlemann K, Laeuffer J, Decker-Burgard S, Cassettari M, Morrissey I. Susceptibility of Gram-negative pathogens to ceftobiprole, ceftazidime and cefepime isolated from centres in Austria, Germany and Switzerland. Clin Microbiol Infect. 2010; 16: S357.
  • Shang W, Davies TA, Flamm RK, Bush K. Effects of ceftobiprole and oxacillin on mecA expression in methicillin-resistant Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2010; 54(2): 956-959.
  • Silva N, Radhouani H, Gonçalves A, Araújo C, Rodrigues J, Igrejas G, Poeta P. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals. J Antimicrob Chemother. 2010; 65(4): 801-803.
  • Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(2): 610-613.
  • Tobudic S, Poppl W, Kratzer C, Graninger W, Burgmann H. In vitro evaluation of the bactericidal activities of MRSA active antibiotics in four different peritoneal dialyses fluids. Clin Microbiol Infect. 2010; 16: S9-S10.
  • Torres C, Cercenado E. Interpretive reading of the antibiogram in gram positive COCCI. Enferm Infecc Microbiol Clin. 2010; 28(8): 541-553. 
  • Vardakas K, Mavros M, Roussos N, Falagas M. Vancomycin for the treatment of patients with Gram-positive infections: A meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2010; 16: S452.

  • Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: Current and future options. Int J Antimicrob Agents. 2010; 36(5): 391-400.

  • Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, Hoban DJ. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance study (CANWARD 2008). Antimicrob Agents Chemother. 2010;  54(11): 4684-4693.
 

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC, September 2010, Boston, United States of America

 
  • A1-1376 / Pharmacodynamic (PD) activity of ceftobiprole (Cefto) compared to vancomycin (Vanco) vs. enterococcus faecalis using an in vitro model. Zhanel GG, Laing N,  Cox L, Rossnagel E, Voth D, Karlowsky JA, Hoban DJ.
  • B-061 / Efficacy of ceftobiprole (BPR) alone and in combination with vancomycin (VAN) in a rat MRSA infective endocarditis (IE) model. Fernandez J, Abbanat D, Flamm RK, Hastings J, Barron AM, Lynch AS.
  • B-062 / In vivo synergism of ceftobiprole in combination with vancomycin against experimental endocarditis due to vancomycin-intermediate staphylococcus aureus. Vouillamoz J, Entenza JM, Veloso TR, Giddey M, Moreillon P.
  • C2-117 / Characterization of β-lactamase negative ampicillin-resistant (BLNAR) and β-lactamase positive amoxicillin-clavulanate-resistant (BLPACR) haemophilus influenzae. Davies TA, Stevenson AE, He W, Noel GJ, Pelton SI.
  • E-818 / In vitro activities of ceftaroline and ceftobiprole against penicillin- and macrolide-non-susceptible streptococcus pneumoniae (SPN)-CANWARD 2009. Wierzbowski AK, Adam HJ, Karlowsky J, Hoban DJ, Zhanel GG.
  • E-1562 / Effects of ceftobiprole and comparators alone and in combination in an in vitro staphylococcal biofilm model. Abbanat D, Santoro C, Shang W, Baum E, Crespo-Carbone S, Lynch AS.
  • E-2043 / In vitro activities of ceftobiprole and doripenem against major bacterial isolates of hospital-acquired pneumonia in Asian countries: An ANSORP study. Kim S, Song J, Chung D, Lee M, Ko K, Ansorp Study Group.     

 

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-939 / Trends in ceftobiprole susceptibility among 2001-2008 consecutive methicillin-resistant Staphylococcus aureus blood isolates. Golan Y, McDermott L, Snydman DR.
  • P-1226 / Effect of ceftobiprole on the normal human intestinal microflora. Panagiotidis G, Bäckström T, Asker-Hagelberg C, Rashid M, Weintraub A, Nord CE.
  • P-1269 / Susceptibility of Gram-negative pathogens to ceftobiprole, ceftazidime and cefepime isolated from centres in Austria, Germany and Switzerland. Seifert H, Gatermann S, Pfister W, Poehlmann C, Huhulescu S, Muehlemann K, Laeuffer J, Decker-Burgard S, Cassettari M, Morrissey I.
  • P-1875 / Ceftobiprole activity when tested against clinical bacterial pathogens from Europe, 2009. Farrell D, Moet G, Sader H, Putnam S, Jones R. 
 

Isavuconazole

  • Badali H, Bonifaz A, Barrón-Tapia T, Vázquez-González D, Estrada-Aguilar L, Cavalcante Oliveira NM, Sobral Filho JF, Guarro J, Meis JFGM, De Hoog GS. Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Med Mycol. 2010; 48(5): 696-703.
  • Badali H, Chander J, Gulati N, Attri A, Chopra R, Najafzadeh MJ, Chhabra S, Meis JFGM, De Hoog GS. Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi. Med Mycol. 2010; 48(5): 763-768.
  • Badali H, De Hoog GS, Curfs-Breuker I, Klaassen CHW, Meis JF. Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility. J Clin Microbiol. 2010; 48(7): 2350-2356.
  • Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. Apophysomyces elegans: Epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol. 2010; 48(12): 4580-4585.
  • Ekiert RJ, Krzek J, Talik P. Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents - A review. Talanta. 2010; 82(4): 1090-1100.
  • Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Rüping MJGT, Müller C.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010; 54(5): 1815-1819.
  • Farowski F, Müller C, Rüping MJGT, Vehreschild JJ, Cornely OA. Intracellular concentrations of echinocandin antifungals. Mycoses. 2010; 53(5): 419-420.
  • Farowski F, Müller C, Rüping MJGT, Vehreschild JJ, Cornely OA. Intracellular concentrations of echinocandins in different compartments of the peripheral blood. Onkologie. 2010; 33(6): 68.
  • Guinea J, Recio S, Escribano P, Peláez T, Torres-Narbona M, Rodriguez-Créixems M, Sánchez-Carrillo C, Bouza E. Antifungal susceptibility of yeasts isolated from patients with fungaemia: comparison of the E-test on direct blood samples and CLSI M27-A3. Clin Microbiol Infect. 2010; 16: S217.
  • Guinea J, Hagen F, Peláez T, Boekhout T, Tahoune H, Torres-Narbona M, Bouza E. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol. 2010; 48(7): 942-948. 
  • Guinea J, Escribano P, Recio S, Peláez T, Bouza E. Can isavuconazole MICs for yeasts be read after 24 hours of incubation? Clin Microbiol Infect. 2010; 16: S217-S218.
  • Guinea J, Recio S, Escribano P, Peláez T, Bouza E. In vitro activity of isavuconazole against clinical non-Candida yeast isolates determined by E-test and CLSI M27-A3. Clin Microbiol Infect. 2010; 16: S218.
  • Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother. 2010; 54(9): 4012-4015. 
  • Guinea J, Recio S, Escribano P, Torres-Narbona M, Peláez T, Sánchez-Carrillo C, Rodríguez-Créixems M, Bouza E. Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia. J Clin Microbiol. 2010; 48(6): 2205-2212.
  • Hagen F, Illnait-Zaragozi M-T, Bartlett KH, Swinne D, Geertsen E, Klaassen CHW, Boekhout T, Meis JF. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother. 2010; 54(12): 5139-5145.
  • Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM, Hagen F, Boekhout T, Klaassen CHW, Meis JF. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis. 2010; 10: 289. 
  • Najafzadeh MJ, Badali H, Illnait-Zaragozi MT, De Hoog GS, Meis JF. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrob Agents Chemother. 2010; 54(4): 1636-1638.
  • Pappas PG. Opportunistic fungi: A view to the future. Am J Med Sci. 2010; 340(3): 253-257. 
  • Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: Focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Invest Drugs. 2010; 11(2): 164-174.
  • Thompson III GR, Wiederhold NP. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010; 170(5): 291-313. 
  • Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MGP, Arisawa M. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int J Antimicrob Agents. 2010.

     

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC, September 2010, Boston, United States of America

 
  • M-375 / Isavuconazole wild-type (WT) MIC distributions and epidemiological cut-off values (ECVs) for clinical isolates of aspergillus spp. Peláez T, Espinel-Ingroff A, Gama B, Reigadas E, Guinea J, Alcalá L, Muñoz P, Bouza E.
 

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-838 / Antifungal susceptibility of yeasts isolated from patients with fungaemia: comparison of the E-test on direct blood samples and CLSI M27-A3. Guinea J, Recio S, Escribano P, Peláez T, Torres-Narbona M, Rodríguez-Créixems M, Sánchez-Carrillo C, Bouza E.
  • P-839 / Can isavuconazole MICs for yeasts be read after 24 hours of incubation? Guinea J, Escribano P, Recio S, Peláez T, Bouza E.
  • P-840 / In vitro activity of isavuconazole against clinical non-Candida yeast isolates determined by E-test and CLSI M27-A3. Guinea J, Recio S, Escribano P, Peláez T, Bouza E.
 

Research

50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC, September 2010, Boston, United States of America

 
  • F1-2132 / The role of the siderophore moiety in the activity of the novel monosulfactam BAL30072. Page MGP, Richalet F, Müller C, Hofer B, Desarbre E.
  • F1-2133 / Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against acinetobacter in iron-limited conditions. Page MG, Müller C, Hofer B, Desarbre E.
  • F1-2134 / Exploring Novel Inhibitors of FOX-4 Class C β-Lactamase. Mallo S, Bethel C,  Perez-Llarena F, Prati F, Caselli E, Page M, Bou G, Bonomo R.
  • C1-1961 / CMY-33, a novel extended spectrum beta-lactamase (ESBL) of the CMY-2 family. Taracila M, Endimiani A, Bethel CR, Doi Y, Page MGP, Bonomo RA.  

 

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-1240 / Efficacy of BAL30072, alone and combined with meropenem, against VIM-producing enterobacteria in a murine thigh infection model. Miriagou V, Papagiannitsis C, Kotsakis S, Zioga A, Siatravani E, Loli A, Tzelepi E, Tzouvelekis T, Donzelli M, Spickermann J, Page M.
  • P-1241 / The role of iron transport in the activity of the siderophore sulfactam BAL30072 against Pseudomonas aeruginosa. Page M, Müller C, Hofer B, Desarbre E, Dreier J, Vidal F.
 
Info